• Explore /
  • Poster
  • / Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC).

Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC).

Abstract Poster

Authors

Yi-Long Wu

Yi-Long Wu

Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China

Yi-Long Wu , Dong-Wan Kim , Enriqueta Felip , Li Zhang , Xiaoqing Liu , Cai Cun Zhou , Dae Ho Lee , Ji-Youn Han , Alexander Krohn , Rachel Lebouteiller , Cindy Xu , Matthew Squires , Mikhail Akimov , Daniel Shao-Weng Tan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01610336

Citation

J Clin Oncol 34, 2016 (suppl; abstr 9020)

DOI

10.1200/JCO.2016.34.15_suppl.9020

Abstract #

9020

Poster Bd #

343

Abstract Disclosures

Similar Posters

First Author: Yi-Long Wu

First Author: Qing Zhou

First Author: Rosario Garcia Campelo

First Author: Yoshikazu Hasegawa